Pentixapharm's CXCR4 Compound Showcased at EANM Conference

In Hamburg, Germany, Pentixapharm Holding AG's CXCR4 targeting compounds are being highlighted through 17 abstract presentations at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) from October 19 to 23, 2024. The presentations focus on diagnostic and therapeutic applications in a range of conditions, including high-grade gliomas and cardiovascular diseases. Economic implications of CXCR4-directed molecular imaging are also discussed.

Dr. Dirk Pleimes, Pentixapharm’s Chief Medical Officer, expressed enthusiasm over showcasing CXCR4 targeting compounds at a major nuclear medicine event, pointing to significant interest from academia in the field. Attendees are invited for further discussions at Pentixapharm’s booth in Hall H, stand H19.